[의학] 통풍치료제-레시누라드(lesinurad)

 1  [의학] 통풍치료제-레시누라드(lesinurad)-1
 2  [의학] 통풍치료제-레시누라드(lesinurad)-2
 3  [의학] 통풍치료제-레시누라드(lesinurad)-3
 4  [의학] 통풍치료제-레시누라드(lesinurad)-4
 5  [의학] 통풍치료제-레시누라드(lesinurad)-5
 6  [의학] 통풍치료제-레시누라드(lesinurad)-6
 7  [의학] 통풍치료제-레시누라드(lesinurad)-7
 8  [의학] 통풍치료제-레시누라드(lesinurad)-8
 9  [의학] 통풍치료제-레시누라드(lesinurad)-9
 10  [의학] 통풍치료제-레시누라드(lesinurad)-10
 11  [의학] 통풍치료제-레시누라드(lesinurad)-11
 12  [의학] 통풍치료제-레시누라드(lesinurad)-12
 13  [의학] 통풍치료제-레시누라드(lesinurad)-13
 14  [의학] 통풍치료제-레시누라드(lesinurad)-14
 15  [의학] 통풍치료제-레시누라드(lesinurad)-15
 16  [의학] 통풍치료제-레시누라드(lesinurad)-16
 17  [의학] 통풍치료제-레시누라드(lesinurad)-17
 18  [의학] 통풍치료제-레시누라드(lesinurad)-18
 19  [의학] 통풍치료제-레시누라드(lesinurad)-19
 20  [의학] 통풍치료제-레시누라드(lesinurad)-20
※ 미리보기 이미지는 최대 20페이지까지만 지원합니다.
  • 분야
  • 등록일
  • 페이지/형식
  • 구매가격
  • 적립금
자료 다운로드  네이버 로그인
소개글
[의학] 통풍치료제-레시누라드(lesinurad)에 대한 자료입니다.
목차
1.INTRODUCTION
-What is gout
-How to treat
-Cause / Drug of gout

2.DRUG INFORMATION
-Lesinurad as a URAT1 inhibitor

3.CLINICAL TRIAL
본문내용
WHAT IS GOUT
Gout
caused by abnormally elevated levels of uric acid  in the blood (sUA *> 6.8mg/dL ) resulting in a build-up uric acid crystals throughout the body
* sUA :serum uric acid

Hyperuricemia
linked to elevated hypertension in adults and children
increased mortality in Chronic Kidney Disease and possibly other cardiovascular risk factors, including elevated C-Reactive Protein



Increasing incidence and severity in US approximately 8 million patients

HOW TO TREAT
Two goals for treatment of hyperuricemia /gout
Acute treatment for inflammation
NSAIDS , colchicine, corticosteroid, IL‐1 inhibitor
Chronic treatment to lower serum uric acid
Uricosurics : benzobromarone , probenecid, sulfinpyrazone
Xanthine oxidase inhibitors : allopurinol, febuxostat (FBX)
Uricase : pegloticase


참고문헌
Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat, January 2010
Ken Okamoto and Takeshi Nishino, Crystral structures of mammalian xanthine oxidoreductase bound with various inhibitor: allopurinol, febuxostat, and FYX-051
L-T.Yeh 외 8명, Safety, phamacokinetics, and serum uric acid lowering effect of RDEA594, a novel uricosuric agent, in healthy volunteers, June 10, 2009
Z.shen 외 9명, Lesinurad , A novel URAT1 Inhibitor, Shows Additive Serum Urate Lowring Effecrs in Combination with Xanthine Oxidase Inhibitor Febuxostat
X Yang 외 7명, Evaluation of drug-drug interacion potential between RDEA594, Allopurinol and Febuxostat in preclinical species, October 16, 2009
Sasha B. Coffiner, Ardea seeks partner for RDEA 594 in gout, executive says; may be effective in combination with febuxustat, allopurinol – rheumatologists, July 2, 2010
R. Fleischmann 외 9명, Lesinurad (RDEA594), A Novel Oral Uricosuric Agent, in combination with Febuxostat Shows Significant Additive Urate Lowering Effects in Gout Subjects with 100% Response Achieved for All Combination Dose Regimens, May 25, 2011